Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,024
archived clinical trials in
Infectious Disease

Safety and Immunogenicity of Sequential Rotavirus Vaccine Schedules
Safety and Immunogenicity of Sequential Rotavirus Vaccine Schedules With RotaTeq® and Rotarix®
Status: Enrolling
Updated:  3/28/2013
Seattle Children's Hospital - Infectious Diseases
mi
from
Seattle, WA
Safety and Immunogenicity of Sequential Rotavirus Vaccine Schedules
Safety and Immunogenicity of Sequential Rotavirus Vaccine Schedules With RotaTeq® and Rotarix®
Status: Enrolling
Updated: 3/28/2013
Seattle Children's Hospital - Infectious Diseases
mi
from
Seattle, WA
Click here to add this to my saved trials
Pharmacokinetics, Safety and Tolerability of Escalating Rifapentine Doses in Healthy Volunteers
Phase I Dose Escalation Study of the Pharmacokinetics, Safety and Tolerability of Rifapentine and the Effects of Increasing Doses of Rifapentine on Induction of Metabolizing Enzymes in Healthy Volunteers
Status: Enrolling
Updated:  4/1/2013
Johns Hopkins University
mi
from
Baltimore, MD
Pharmacokinetics, Safety and Tolerability of Escalating Rifapentine Doses in Healthy Volunteers
Phase I Dose Escalation Study of the Pharmacokinetics, Safety and Tolerability of Rifapentine and the Effects of Increasing Doses of Rifapentine on Induction of Metabolizing Enzymes in Healthy Volunteers
Status: Enrolling
Updated: 4/1/2013
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
The Impact of Proton Pump Inhibitors on the Fecal Microbiome
The Impact of Proton Pump Inhibitors on the Fecal Microbiome and Their Relationship to Clostridium Difficile Infection
Status: Enrolling
Updated:  4/2/2013
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
The Impact of Proton Pump Inhibitors on the Fecal Microbiome
The Impact of Proton Pump Inhibitors on the Fecal Microbiome and Their Relationship to Clostridium Difficile Infection
Status: Enrolling
Updated: 4/2/2013
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Study of Hepatitis C Virus (HCV) Entry Inhibitor in Liver Transplant Recipients With HCV Infection
Phase I Study of Hepatitis C Virus (HCV) Entry Inhibitor (ITX 5061) in Liver Transplant Recipients With HCV Infection
Status: Enrolling
Updated:  4/16/2013
Mount Sinai School of Medicine
mi
from
New York, NY
Study of Hepatitis C Virus (HCV) Entry Inhibitor in Liver Transplant Recipients With HCV Infection
Phase I Study of Hepatitis C Virus (HCV) Entry Inhibitor (ITX 5061) in Liver Transplant Recipients With HCV Infection
Status: Enrolling
Updated: 4/16/2013
Mount Sinai School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
A Phase 2, Multicenter, Open-label Study to Assess the Immunogenicity of an Investigational Hib Vaccine (NU300)in Toddlers
A Phase 2, Multicenter, Randomized, Double-Blind, Immunogenicity, Reactogenicity, and Safety Study of NU300 Booster Dose Compared to ActHIB®, Both Co-administered With Prevnar 13® at 12-15 Months of Age, in Healthy Toddlers Who Have Received a Primary Series of a Licensed Hib Vaccine and Prevnar 13®
Status: Enrolling
Updated:  4/19/2013
Clinical Research Facility
mi
from
Santa Clara, CA
A Phase 2, Multicenter, Open-label Study to Assess the Immunogenicity of an Investigational Hib Vaccine (NU300)in Toddlers
A Phase 2, Multicenter, Randomized, Double-Blind, Immunogenicity, Reactogenicity, and Safety Study of NU300 Booster Dose Compared to ActHIB®, Both Co-administered With Prevnar 13® at 12-15 Months of Age, in Healthy Toddlers Who Have Received a Primary Series of a Licensed Hib Vaccine and Prevnar 13®
Status: Enrolling
Updated: 4/19/2013
Clinical Research Facility
mi
from
Santa Clara, CA
Click here to add this to my saved trials
A Phase 2, Multicenter, Open-label Study to Assess the Immunogenicity of an Investigational Hib Vaccine (NU300)in Toddlers
A Phase 2, Multicenter, Randomized, Double-Blind, Immunogenicity, Reactogenicity, and Safety Study of NU300 Booster Dose Compared to ActHIB®, Both Co-administered With Prevnar 13® at 12-15 Months of Age, in Healthy Toddlers Who Have Received a Primary Series of a Licensed Hib Vaccine and Prevnar 13®
Status: Enrolling
Updated:  4/19/2013
Clinical Research Facility
mi
from
Louisville, KY
A Phase 2, Multicenter, Open-label Study to Assess the Immunogenicity of an Investigational Hib Vaccine (NU300)in Toddlers
A Phase 2, Multicenter, Randomized, Double-Blind, Immunogenicity, Reactogenicity, and Safety Study of NU300 Booster Dose Compared to ActHIB®, Both Co-administered With Prevnar 13® at 12-15 Months of Age, in Healthy Toddlers Who Have Received a Primary Series of a Licensed Hib Vaccine and Prevnar 13®
Status: Enrolling
Updated: 4/19/2013
Clinical Research Facility
mi
from
Louisville, KY
Click here to add this to my saved trials
A Phase I Clinical Trial Immunizing Healthy Adults With the NMRC-M3V-Ad-PfCA Vaccine to Generate Biologic Reagents
A Phase I Clinical Trial Immunizing Healthy Adults With the NMRC-M3V-Ad-PfCA Vaccine to Generate Biologic Reagents for Refining Immunologic Assays Supporting the Development of the Protective Malaria Vaccine NMRC-M3V-D/Ad-PfCA (AdBa)
Status: Enrolling
Updated:  4/25/2013
Naval Medical Research Center Clinical Trials Center
mi
from
Bethesda, MD
A Phase I Clinical Trial Immunizing Healthy Adults With the NMRC-M3V-Ad-PfCA Vaccine to Generate Biologic Reagents
A Phase I Clinical Trial Immunizing Healthy Adults With the NMRC-M3V-Ad-PfCA Vaccine to Generate Biologic Reagents for Refining Immunologic Assays Supporting the Development of the Protective Malaria Vaccine NMRC-M3V-D/Ad-PfCA (AdBa)
Status: Enrolling
Updated: 4/25/2013
Naval Medical Research Center Clinical Trials Center
mi
from
Bethesda, MD
Click here to add this to my saved trials
A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4893 in Healthy Adult Subjects
A Phase 1, Randomized, Double-blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4893, an Extended Half-Life Human Monoclonal Antibody Against Staphylococcus Aureus Alpha Toxin, in Healthy Adult Subjects
Status: Enrolling
Updated:  4/30/2013
Miami Research Associates
mi
from
South Miami, FL
A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4893 in Healthy Adult Subjects
A Phase 1, Randomized, Double-blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4893, an Extended Half-Life Human Monoclonal Antibody Against Staphylococcus Aureus Alpha Toxin, in Healthy Adult Subjects
Status: Enrolling
Updated: 4/30/2013
Miami Research Associates
mi
from
South Miami, FL
Click here to add this to my saved trials
Safety and Efficacy Evaluation of Topical AL-60371 Otic Suspension, 0.3% in the Treatment of Acute Otitis Externa
Safety and Efficacy Evaluation of Topical AL-60371 Otic Suspension, 0.3% in the Treatment of Acute Otitis Externa
Status: Enrolling
Updated:  5/2/2013
Call Alcon Call Center for Trial Locations
mi
from
Fort Worth, TX
Safety and Efficacy Evaluation of Topical AL-60371 Otic Suspension, 0.3% in the Treatment of Acute Otitis Externa
Safety and Efficacy Evaluation of Topical AL-60371 Otic Suspension, 0.3% in the Treatment of Acute Otitis Externa
Status: Enrolling
Updated: 5/2/2013
Call Alcon Call Center for Trial Locations
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Internet-Based Sexual Health Education for Middle School Native American Youth
It's Your Game...Keep It Real for American Indian/Alaska Native Youth: Innovative Approaches to Prevent Teen Pregnancy Among Underserved Populations
Status: Enrolling
Updated:  5/4/2013
Alaska Native Tribal Health Consortium
mi
from
Anchorage, AK
Internet-Based Sexual Health Education for Middle School Native American Youth
It's Your Game...Keep It Real for American Indian/Alaska Native Youth: Innovative Approaches to Prevent Teen Pregnancy Among Underserved Populations
Status: Enrolling
Updated: 5/4/2013
Alaska Native Tribal Health Consortium
mi
from
Anchorage, AK
Click here to add this to my saved trials
Internet-Based Sexual Health Education for Middle School Native American Youth
It's Your Game...Keep It Real for American Indian/Alaska Native Youth: Innovative Approaches to Prevent Teen Pregnancy Among Underserved Populations
Status: Enrolling
Updated:  5/4/2013
Inter Tribal Council of Arizona, Inc.
mi
from
Phoenix, AZ
Internet-Based Sexual Health Education for Middle School Native American Youth
It's Your Game...Keep It Real for American Indian/Alaska Native Youth: Innovative Approaches to Prevent Teen Pregnancy Among Underserved Populations
Status: Enrolling
Updated: 5/4/2013
Inter Tribal Council of Arizona, Inc.
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Internet-Based Sexual Health Education for Middle School Native American Youth
It's Your Game...Keep It Real for American Indian/Alaska Native Youth: Innovative Approaches to Prevent Teen Pregnancy Among Underserved Populations
Status: Enrolling
Updated:  5/4/2013
Northwest Portland Area Indian Health Board
mi
from
Portland, OR
Internet-Based Sexual Health Education for Middle School Native American Youth
It's Your Game...Keep It Real for American Indian/Alaska Native Youth: Innovative Approaches to Prevent Teen Pregnancy Among Underserved Populations
Status: Enrolling
Updated: 5/4/2013
Northwest Portland Area Indian Health Board
mi
from
Portland, OR
Click here to add this to my saved trials
Internet-Based Sexual Health Education for Middle School Native American Youth
It's Your Game...Keep It Real for American Indian/Alaska Native Youth: Innovative Approaches to Prevent Teen Pregnancy Among Underserved Populations
Status: Enrolling
Updated:  5/4/2013
University of Texas Health Science Center at Houston
mi
from
Houston, TX
Internet-Based Sexual Health Education for Middle School Native American Youth
It's Your Game...Keep It Real for American Indian/Alaska Native Youth: Innovative Approaches to Prevent Teen Pregnancy Among Underserved Populations
Status: Enrolling
Updated: 5/4/2013
University of Texas Health Science Center at Houston
mi
from
Houston, TX
Click here to add this to my saved trials
Comparison of Supportive Therapies for Symptom Relief From Pediatric Upper Respiratory Infections (URIs)
Comparison of Supportive Therapies for Symptom Relief From Pediatric Upper Respiratory Infections (URIs)
Status: Enrolling
Updated:  5/6/2013
University of California - San Francisco
mi
from
San Francisco, CA
Comparison of Supportive Therapies for Symptom Relief From Pediatric Upper Respiratory Infections (URIs)
Comparison of Supportive Therapies for Symptom Relief From Pediatric Upper Respiratory Infections (URIs)
Status: Enrolling
Updated: 5/6/2013
University of California - San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Intradermal Versus Intramuscular Polio Vaccine Booster in HIV-Infected Subjects
Comparison of the Immunogenicity of Various Inactivated Polio Vaccine Booster Doses by Intradermal vs. Intramuscular Routes in HIV-Infected Subjects
Status: Enrolling
Updated:  5/14/2013
C3ID Clinic, Eastern Virginia Medical School
mi
from
Norfolk, VA
Intradermal Versus Intramuscular Polio Vaccine Booster in HIV-Infected Subjects
Comparison of the Immunogenicity of Various Inactivated Polio Vaccine Booster Doses by Intradermal vs. Intramuscular Routes in HIV-Infected Subjects
Status: Enrolling
Updated: 5/14/2013
C3ID Clinic, Eastern Virginia Medical School
mi
from
Norfolk, VA
Click here to add this to my saved trials
Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose
A Phase IV, Open-label, Controlled, Multi-center Study to Evaluate the 5-year Antibody Persistence Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine at 2 to 10 Years of Age and to Assess the Immune Response to a Single Dose of Novartis MenACWY Conjugate Vaccine
Status: Enrolling
Updated:  5/30/2013
82 Children s Inv Research Prgm (ChIRP) 2900 Medical Center Parkway, Ste. 300
mi
from
Bentonville, AR
Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose
A Phase IV, Open-label, Controlled, Multi-center Study to Evaluate the 5-year Antibody Persistence Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine at 2 to 10 Years of Age and to Assess the Immune Response to a Single Dose of Novartis MenACWY Conjugate Vaccine
Status: Enrolling
Updated: 5/30/2013
82 Children s Inv Research Prgm (ChIRP) 2900 Medical Center Parkway, Ste. 300
mi
from
Bentonville, AR
Click here to add this to my saved trials
Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose
A Phase IV, Open-label, Controlled, Multi-center Study to Evaluate the 5-year Antibody Persistence Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine at 2 to 10 Years of Age and to Assess the Immune Response to a Single Dose of Novartis MenACWY Conjugate Vaccine
Status: Enrolling
Updated:  5/30/2013
83 AR Pediatric Clinical Research 500 South University, Ste. 200
mi
from
Little Rock, AR
Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose
A Phase IV, Open-label, Controlled, Multi-center Study to Evaluate the 5-year Antibody Persistence Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine at 2 to 10 Years of Age and to Assess the Immune Response to a Single Dose of Novartis MenACWY Conjugate Vaccine
Status: Enrolling
Updated: 5/30/2013
83 AR Pediatric Clinical Research 500 South University, Ste. 200
mi
from
Little Rock, AR
Click here to add this to my saved trials
Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose
A Phase IV, Open-label, Controlled, Multi-center Study to Evaluate the 5-year Antibody Persistence Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine at 2 to 10 Years of Age and to Assess the Immune Response to a Single Dose of Novartis MenACWY Conjugate Vaccine
Status: Enrolling
Updated:  5/30/2013
32 Prem Health Research Center 9317 Firestone Blvd.
mi
from
Downey, CA
Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose
A Phase IV, Open-label, Controlled, Multi-center Study to Evaluate the 5-year Antibody Persistence Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine at 2 to 10 Years of Age and to Assess the Immune Response to a Single Dose of Novartis MenACWY Conjugate Vaccine
Status: Enrolling
Updated: 5/30/2013
32 Prem Health Research Center 9317 Firestone Blvd.
mi
from
Downey, CA
Click here to add this to my saved trials
Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose
A Phase IV, Open-label, Controlled, Multi-center Study to Evaluate the 5-year Antibody Persistence Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine at 2 to 10 Years of Age and to Assess the Immune Response to a Single Dose of Novartis MenACWY Conjugate Vaccine
Status: Enrolling
Updated:  5/30/2013
27 KY Pediatric Adult Research 201 South 5th Street, Suite 102
mi
from
Bardstown, KY
Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose
A Phase IV, Open-label, Controlled, Multi-center Study to Evaluate the 5-year Antibody Persistence Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine at 2 to 10 Years of Age and to Assess the Immune Response to a Single Dose of Novartis MenACWY Conjugate Vaccine
Status: Enrolling
Updated: 5/30/2013
27 KY Pediatric Adult Research 201 South 5th Street, Suite 102
mi
from
Bardstown, KY
Click here to add this to my saved trials
Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose
A Phase IV, Open-label, Controlled, Multi-center Study to Evaluate the 5-year Antibody Persistence Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine at 2 to 10 Years of Age and to Assess the Immune Response to a Single Dose of Novartis MenACWY Conjugate Vaccine
Status: Enrolling
Updated:  5/30/2013
36 Meridian Clinical Research 3319 N. 107th Street
mi
from
Omaha, NE
Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose
A Phase IV, Open-label, Controlled, Multi-center Study to Evaluate the 5-year Antibody Persistence Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine at 2 to 10 Years of Age and to Assess the Immune Response to a Single Dose of Novartis MenACWY Conjugate Vaccine
Status: Enrolling
Updated: 5/30/2013
36 Meridian Clinical Research 3319 N. 107th Street
mi
from
Omaha, NE
Click here to add this to my saved trials
Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose
A Phase IV, Open-label, Controlled, Multi-center Study to Evaluate the 5-year Antibody Persistence Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine at 2 to 10 Years of Age and to Assess the Immune Response to a Single Dose of Novartis MenACWY Conjugate Vaccine
Status: Enrolling
Updated:  5/30/2013
33 Dr. Sender's and Associates 2054 South Green Road
mi
from
Cleveland, OH
Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose
A Phase IV, Open-label, Controlled, Multi-center Study to Evaluate the 5-year Antibody Persistence Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine at 2 to 10 Years of Age and to Assess the Immune Response to a Single Dose of Novartis MenACWY Conjugate Vaccine
Status: Enrolling
Updated: 5/30/2013
33 Dr. Sender's and Associates 2054 South Green Road
mi
from
Cleveland, OH
Click here to add this to my saved trials
Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose
A Phase IV, Open-label, Controlled, Multi-center Study to Evaluate the 5-year Antibody Persistence Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine at 2 to 10 Years of Age and to Assess the Immune Response to a Single Dose of Novartis MenACWY Conjugate Vaccine
Status: Enrolling
Updated:  5/30/2013
31 Benchmark Research, Fort Worth 4504 Boat Club Rd., Suite 400A
mi
from
Ft. Worth, TX
Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose
A Phase IV, Open-label, Controlled, Multi-center Study to Evaluate the 5-year Antibody Persistence Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine at 2 to 10 Years of Age and to Assess the Immune Response to a Single Dose of Novartis MenACWY Conjugate Vaccine
Status: Enrolling
Updated: 5/30/2013
31 Benchmark Research, Fort Worth 4504 Boat Club Rd., Suite 400A
mi
from
Ft. Worth, TX
Click here to add this to my saved trials
Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose
A Phase IV, Open-label, Controlled, Multi-center Study to Evaluate the 5-year Antibody Persistence Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine at 2 to 10 Years of Age and to Assess the Immune Response to a Single Dose of Novartis MenACWY Conjugate Vaccine
Status: Enrolling
Updated:  5/30/2013
25 Benchmark Research, San Angelo 3555 Knickerbocker Rd.
mi
from
San Angelo, TX
Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose
A Phase IV, Open-label, Controlled, Multi-center Study to Evaluate the 5-year Antibody Persistence Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine at 2 to 10 Years of Age and to Assess the Immune Response to a Single Dose of Novartis MenACWY Conjugate Vaccine
Status: Enrolling
Updated: 5/30/2013
25 Benchmark Research, San Angelo 3555 Knickerbocker Rd.
mi
from
San Angelo, TX
Click here to add this to my saved trials
Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose
A Phase IV, Open-label, Controlled, Multi-center Study to Evaluate the 5-year Antibody Persistence Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine at 2 to 10 Years of Age and to Assess the Immune Response to a Single Dose of Novartis MenACWY Conjugate Vaccine
Status: Enrolling
Updated:  5/30/2013
65 Westside Medical 1477 N 2000 W, Suite C
mi
from
Clinton, UT
Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose
A Phase IV, Open-label, Controlled, Multi-center Study to Evaluate the 5-year Antibody Persistence Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine at 2 to 10 Years of Age and to Assess the Immune Response to a Single Dose of Novartis MenACWY Conjugate Vaccine
Status: Enrolling
Updated: 5/30/2013
65 Westside Medical 1477 N 2000 W, Suite C
mi
from
Clinton, UT
Click here to add this to my saved trials
Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose
A Phase IV, Open-label, Controlled, Multi-center Study to Evaluate the 5-year Antibody Persistence Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine at 2 to 10 Years of Age and to Assess the Immune Response to a Single Dose of Novartis MenACWY Conjugate Vaccine
Status: Enrolling
Updated:  5/30/2013
29 J. Lewis Research, Inc. 6360 South 3000 East, Ste. 100
mi
from
Salt Lake City, UT
Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose
A Phase IV, Open-label, Controlled, Multi-center Study to Evaluate the 5-year Antibody Persistence Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine at 2 to 10 Years of Age and to Assess the Immune Response to a Single Dose of Novartis MenACWY Conjugate Vaccine
Status: Enrolling
Updated: 5/30/2013
29 J. Lewis Research, Inc. 6360 South 3000 East, Ste. 100
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose
A Phase IV, Open-label, Controlled, Multi-center Study to Evaluate the 5-year Antibody Persistence Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine at 2 to 10 Years of Age and to Assess the Immune Response to a Single Dose of Novartis MenACWY Conjugate Vaccine
Status: Enrolling
Updated:  5/30/2013
30 J. Lewis Research, Inc. 6360 South 3000 East, Ste. 100
mi
from
Salt Lake City, UT
Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose
A Phase IV, Open-label, Controlled, Multi-center Study to Evaluate the 5-year Antibody Persistence Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine at 2 to 10 Years of Age and to Assess the Immune Response to a Single Dose of Novartis MenACWY Conjugate Vaccine
Status: Enrolling
Updated: 5/30/2013
30 J. Lewis Research, Inc. 6360 South 3000 East, Ste. 100
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose
A Phase IV, Open-label, Controlled, Multi-center Study to Evaluate the 5-year Antibody Persistence Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine at 2 to 10 Years of Age and to Assess the Immune Response to a Single Dose of Novartis MenACWY Conjugate Vaccine
Status: Enrolling
Updated:  5/30/2013
37 Copperview Medical Associates 3556 West 9800 South
mi
from
South Jordan, UT
Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose
A Phase IV, Open-label, Controlled, Multi-center Study to Evaluate the 5-year Antibody Persistence Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine at 2 to 10 Years of Age and to Assess the Immune Response to a Single Dose of Novartis MenACWY Conjugate Vaccine
Status: Enrolling
Updated: 5/30/2013
37 Copperview Medical Associates 3556 West 9800 South
mi
from
South Jordan, UT
Click here to add this to my saved trials
Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose
A Phase IV, Open-label, Controlled, Multi-center Study to Evaluate the 5-year Antibody Persistence Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine at 2 to 10 Years of Age and to Assess the Immune Response to a Single Dose of Novartis MenACWY Conjugate Vaccine
Status: Enrolling
Updated:  5/30/2013
47 Wee Care Pediatrics 1792 W. 1700 S.
mi
from
Syracuse, UT
Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose
A Phase IV, Open-label, Controlled, Multi-center Study to Evaluate the 5-year Antibody Persistence Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine at 2 to 10 Years of Age and to Assess the Immune Response to a Single Dose of Novartis MenACWY Conjugate Vaccine
Status: Enrolling
Updated: 5/30/2013
47 Wee Care Pediatrics 1792 W. 1700 S.
mi
from
Syracuse, UT
Click here to add this to my saved trials
Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose
A Phase IV, Open-label, Controlled, Multi-center Study to Evaluate the 5-year Antibody Persistence Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine at 2 to 10 Years of Age and to Assess the Immune Response to a Single Dose of Novartis MenACWY Conjugate Vaccine
Status: Enrolling
Updated:  5/30/2013
34 Rockwood Clinic P S 400 East Fifth Avenue
mi
from
Spokane, WA
Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose
A Phase IV, Open-label, Controlled, Multi-center Study to Evaluate the 5-year Antibody Persistence Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine at 2 to 10 Years of Age and to Assess the Immune Response to a Single Dose of Novartis MenACWY Conjugate Vaccine
Status: Enrolling
Updated: 5/30/2013
34 Rockwood Clinic P S 400 East Fifth Avenue
mi
from
Spokane, WA
Click here to add this to my saved trials
Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose
A Phase IV, Open-label, Controlled, Multi-center Study to Evaluate the 5-year Antibody Persistence Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine at 2 to 10 Years of Age and to Assess the Immune Response to a Single Dose of Novartis MenACWY Conjugate Vaccine
Status: Enrolling
Updated:  5/30/2013
35 Rockwood Clinic-North Pediatrics 9001 N Country Homes Blvd
mi
from
Spokane, WA
Persistence of Immunogenicity of MenACWY Conjugate Vaccine 5 Years After Childhood Vaccination, and Immune Response to a Booster Dose
A Phase IV, Open-label, Controlled, Multi-center Study to Evaluate the 5-year Antibody Persistence Among Children Who Previously Received Novartis MenACWY Conjugate Vaccine at 2 to 10 Years of Age and to Assess the Immune Response to a Single Dose of Novartis MenACWY Conjugate Vaccine
Status: Enrolling
Updated: 5/30/2013
35 Rockwood Clinic-North Pediatrics 9001 N Country Homes Blvd
mi
from
Spokane, WA
Click here to add this to my saved trials
Identigene STD Test Collection Kit Validation Study
Identigene STD Test Collection Kit Validation Study
Status: Enrolling
Updated:  5/31/2013
John Hopkins University
mi
from
Baltimore, MD
Identigene STD Test Collection Kit Validation Study
Identigene STD Test Collection Kit Validation Study
Status: Enrolling
Updated: 5/31/2013
John Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Prospective Collection of Female and Male Specimens for PANTHER® System Testing
Prospective Collection of Female First-catch Urine, Vaginal Swab, Cervical, and Endocervical Swab Specimens and Male Urethral Swab and First-catch Urine Specimens for Testing With the PANTHER® System
Status: Enrolling
Updated:  6/3/2013
University of Alabama at Birmingham
mi
from
Birmingham, AL
Prospective Collection of Female and Male Specimens for PANTHER® System Testing
Prospective Collection of Female First-catch Urine, Vaginal Swab, Cervical, and Endocervical Swab Specimens and Male Urethral Swab and First-catch Urine Specimens for Testing With the PANTHER® System
Status: Enrolling
Updated: 6/3/2013
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Prospective Collection of Female and Male Specimens for PANTHER® System Testing
Prospective Collection of Female First-catch Urine, Vaginal Swab, Cervical, and Endocervical Swab Specimens and Male Urethral Swab and First-catch Urine Specimens for Testing With the PANTHER® System
Status: Enrolling
Updated:  6/3/2013
Anthony Mills MD Inc
mi
from
Los Angeles, CA
Prospective Collection of Female and Male Specimens for PANTHER® System Testing
Prospective Collection of Female First-catch Urine, Vaginal Swab, Cervical, and Endocervical Swab Specimens and Male Urethral Swab and First-catch Urine Specimens for Testing With the PANTHER® System
Status: Enrolling
Updated: 6/3/2013
Anthony Mills MD Inc
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Prospective Collection of Female and Male Specimens for PANTHER® System Testing
Prospective Collection of Female First-catch Urine, Vaginal Swab, Cervical, and Endocervical Swab Specimens and Male Urethral Swab and First-catch Urine Specimens for Testing With the PANTHER® System
Status: Enrolling
Updated:  6/3/2013
Benchmark Research
mi
from
San Francisco, CA
Prospective Collection of Female and Male Specimens for PANTHER® System Testing
Prospective Collection of Female First-catch Urine, Vaginal Swab, Cervical, and Endocervical Swab Specimens and Male Urethral Swab and First-catch Urine Specimens for Testing With the PANTHER® System
Status: Enrolling
Updated: 6/3/2013
Benchmark Research
mi
from
San Francisco, CA
Click here to add this to my saved trials
Prospective Collection of Female and Male Specimens for PANTHER® System Testing
Prospective Collection of Female First-catch Urine, Vaginal Swab, Cervical, and Endocervical Swab Specimens and Male Urethral Swab and First-catch Urine Specimens for Testing With the PANTHER® System
Status: Enrolling
Updated:  6/3/2013
Planned Parenthood Southern New England
mi
from
New Haven, CT
Prospective Collection of Female and Male Specimens for PANTHER® System Testing
Prospective Collection of Female First-catch Urine, Vaginal Swab, Cervical, and Endocervical Swab Specimens and Male Urethral Swab and First-catch Urine Specimens for Testing With the PANTHER® System
Status: Enrolling
Updated: 6/3/2013
Planned Parenthood Southern New England
mi
from
New Haven, CT
Click here to add this to my saved trials
Prospective Collection of Female and Male Specimens for PANTHER® System Testing
Prospective Collection of Female First-catch Urine, Vaginal Swab, Cervical, and Endocervical Swab Specimens and Male Urethral Swab and First-catch Urine Specimens for Testing With the PANTHER® System
Status: Enrolling
Updated:  6/3/2013
AGA Clinical Trials
mi
from
Hialeah, FL
Prospective Collection of Female and Male Specimens for PANTHER® System Testing
Prospective Collection of Female First-catch Urine, Vaginal Swab, Cervical, and Endocervical Swab Specimens and Male Urethral Swab and First-catch Urine Specimens for Testing With the PANTHER® System
Status: Enrolling
Updated: 6/3/2013
AGA Clinical Trials
mi
from
Hialeah, FL
Click here to add this to my saved trials
Prospective Collection of Female and Male Specimens for PANTHER® System Testing
Prospective Collection of Female First-catch Urine, Vaginal Swab, Cervical, and Endocervical Swab Specimens and Male Urethral Swab and First-catch Urine Specimens for Testing With the PANTHER® System
Status: Enrolling
Updated:  6/3/2013
Wishard Health Services
mi
from
Indianapolis, IN
Prospective Collection of Female and Male Specimens for PANTHER® System Testing
Prospective Collection of Female First-catch Urine, Vaginal Swab, Cervical, and Endocervical Swab Specimens and Male Urethral Swab and First-catch Urine Specimens for Testing With the PANTHER® System
Status: Enrolling
Updated: 6/3/2013
Wishard Health Services
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Prospective Collection of Female and Male Specimens for PANTHER® System Testing
Prospective Collection of Female First-catch Urine, Vaginal Swab, Cervical, and Endocervical Swab Specimens and Male Urethral Swab and First-catch Urine Specimens for Testing With the PANTHER® System
Status: Enrolling
Updated:  6/3/2013
Louisiana State University Health Sciences
mi
from
New Orleans, LA
Prospective Collection of Female and Male Specimens for PANTHER® System Testing
Prospective Collection of Female First-catch Urine, Vaginal Swab, Cervical, and Endocervical Swab Specimens and Male Urethral Swab and First-catch Urine Specimens for Testing With the PANTHER® System
Status: Enrolling
Updated: 6/3/2013
Louisiana State University Health Sciences
mi
from
New Orleans, LA
Click here to add this to my saved trials
Prospective Collection of Female and Male Specimens for PANTHER® System Testing
Prospective Collection of Female First-catch Urine, Vaginal Swab, Cervical, and Endocervical Swab Specimens and Male Urethral Swab and First-catch Urine Specimens for Testing With the PANTHER® System
Status: Enrolling
Updated:  6/3/2013
John Hopkins University
mi
from
Lutherville, MD
Prospective Collection of Female and Male Specimens for PANTHER® System Testing
Prospective Collection of Female First-catch Urine, Vaginal Swab, Cervical, and Endocervical Swab Specimens and Male Urethral Swab and First-catch Urine Specimens for Testing With the PANTHER® System
Status: Enrolling
Updated: 6/3/2013
John Hopkins University
mi
from
Lutherville, MD
Click here to add this to my saved trials
Prospective Collection of Female and Male Specimens for PANTHER® System Testing
Prospective Collection of Female First-catch Urine, Vaginal Swab, Cervical, and Endocervical Swab Specimens and Male Urethral Swab and First-catch Urine Specimens for Testing With the PANTHER® System
Status: Enrolling
Updated:  6/3/2013
New England Center for Clinical Research - New Bedford Clinic
mi
from
New Bedford, MA
Prospective Collection of Female and Male Specimens for PANTHER® System Testing
Prospective Collection of Female First-catch Urine, Vaginal Swab, Cervical, and Endocervical Swab Specimens and Male Urethral Swab and First-catch Urine Specimens for Testing With the PANTHER® System
Status: Enrolling
Updated: 6/3/2013
New England Center for Clinical Research - New Bedford Clinic
mi
from
New Bedford, MA
Click here to add this to my saved trials
Prospective Collection of Female and Male Specimens for PANTHER® System Testing
Prospective Collection of Female First-catch Urine, Vaginal Swab, Cervical, and Endocervical Swab Specimens and Male Urethral Swab and First-catch Urine Specimens for Testing With the PANTHER® System
Status: Enrolling
Updated:  6/3/2013
University of North Carolina Chapel Hill
mi
from
Chapel Hill, NC
Prospective Collection of Female and Male Specimens for PANTHER® System Testing
Prospective Collection of Female First-catch Urine, Vaginal Swab, Cervical, and Endocervical Swab Specimens and Male Urethral Swab and First-catch Urine Specimens for Testing With the PANTHER® System
Status: Enrolling
Updated: 6/3/2013
University of North Carolina Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Prospective Collection of Female and Male Specimens for PANTHER® System Testing
Prospective Collection of Female First-catch Urine, Vaginal Swab, Cervical, and Endocervical Swab Specimens and Male Urethral Swab and First-catch Urine Specimens for Testing With the PANTHER® System
Status: Enrolling
Updated:  6/3/2013
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Prospective Collection of Female and Male Specimens for PANTHER® System Testing
Prospective Collection of Female First-catch Urine, Vaginal Swab, Cervical, and Endocervical Swab Specimens and Male Urethral Swab and First-catch Urine Specimens for Testing With the PANTHER® System
Status: Enrolling
Updated: 6/3/2013
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Prospective Collection of Female and Male Specimens for PANTHER® System Testing
Prospective Collection of Female First-catch Urine, Vaginal Swab, Cervical, and Endocervical Swab Specimens and Male Urethral Swab and First-catch Urine Specimens for Testing With the PANTHER® System
Status: Enrolling
Updated:  6/3/2013
Planned Parenthood Houston & Southeast Texas
mi
from
Houston, TX
Prospective Collection of Female and Male Specimens for PANTHER® System Testing
Prospective Collection of Female First-catch Urine, Vaginal Swab, Cervical, and Endocervical Swab Specimens and Male Urethral Swab and First-catch Urine Specimens for Testing With the PANTHER® System
Status: Enrolling
Updated: 6/3/2013
Planned Parenthood Houston & Southeast Texas
mi
from
Houston, TX
Click here to add this to my saved trials
Prospective Collection of Female and Male Specimens for PANTHER® System Testing
Prospective Collection of Female First-catch Urine, Vaginal Swab, Cervical, and Endocervical Swab Specimens and Male Urethral Swab and First-catch Urine Specimens for Testing With the PANTHER® System
Status: Enrolling
Updated:  6/3/2013
Tidewater Clinical Research, Inc. -Tidewater Physicians for Women
mi
from
Norfolk, VA
Prospective Collection of Female and Male Specimens for PANTHER® System Testing
Prospective Collection of Female First-catch Urine, Vaginal Swab, Cervical, and Endocervical Swab Specimens and Male Urethral Swab and First-catch Urine Specimens for Testing With the PANTHER® System
Status: Enrolling
Updated: 6/3/2013
Tidewater Clinical Research, Inc. -Tidewater Physicians for Women
mi
from
Norfolk, VA
Click here to add this to my saved trials
Safety and Efficacy of Multiple Daily Dosing of Oral LFF571 in Patients With Moderate Clostridium Difficile Infections
Multi-center, Randomized, Evaluator-blind, Active-controlled,Parallel-group Design to Determine Safety, Tolerability, and Efficacy of Multiple Daily Administration of LFF571 for 10 Days in Patients With Moderate Clostridium Difficile Infections
Status: Enrolling
Updated:  6/5/2013
Novartis Investigative site
mi
from
Los Angeles, CA
Safety and Efficacy of Multiple Daily Dosing of Oral LFF571 in Patients With Moderate Clostridium Difficile Infections
Multi-center, Randomized, Evaluator-blind, Active-controlled,Parallel-group Design to Determine Safety, Tolerability, and Efficacy of Multiple Daily Administration of LFF571 for 10 Days in Patients With Moderate Clostridium Difficile Infections
Status: Enrolling
Updated: 6/5/2013
Novartis Investigative site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Safety and Efficacy of Multiple Daily Dosing of Oral LFF571 in Patients With Moderate Clostridium Difficile Infections
Multi-center, Randomized, Evaluator-blind, Active-controlled,Parallel-group Design to Determine Safety, Tolerability, and Efficacy of Multiple Daily Administration of LFF571 for 10 Days in Patients With Moderate Clostridium Difficile Infections
Status: Enrolling
Updated:  6/5/2013
Novartis Investigative Site
mi
from
Palm Desert, CA
Safety and Efficacy of Multiple Daily Dosing of Oral LFF571 in Patients With Moderate Clostridium Difficile Infections
Multi-center, Randomized, Evaluator-blind, Active-controlled,Parallel-group Design to Determine Safety, Tolerability, and Efficacy of Multiple Daily Administration of LFF571 for 10 Days in Patients With Moderate Clostridium Difficile Infections
Status: Enrolling
Updated: 6/5/2013
Novartis Investigative Site
mi
from
Palm Desert, CA
Click here to add this to my saved trials
Safety and Efficacy of Multiple Daily Dosing of Oral LFF571 in Patients With Moderate Clostridium Difficile Infections
Multi-center, Randomized, Evaluator-blind, Active-controlled,Parallel-group Design to Determine Safety, Tolerability, and Efficacy of Multiple Daily Administration of LFF571 for 10 Days in Patients With Moderate Clostridium Difficile Infections
Status: Enrolling
Updated:  6/5/2013
Novartis
mi
from
Denver, CO
Safety and Efficacy of Multiple Daily Dosing of Oral LFF571 in Patients With Moderate Clostridium Difficile Infections
Multi-center, Randomized, Evaluator-blind, Active-controlled,Parallel-group Design to Determine Safety, Tolerability, and Efficacy of Multiple Daily Administration of LFF571 for 10 Days in Patients With Moderate Clostridium Difficile Infections
Status: Enrolling
Updated: 6/5/2013
Novartis
mi
from
Denver, CO
Click here to add this to my saved trials
Safety and Efficacy of Multiple Daily Dosing of Oral LFF571 in Patients With Moderate Clostridium Difficile Infections
Multi-center, Randomized, Evaluator-blind, Active-controlled,Parallel-group Design to Determine Safety, Tolerability, and Efficacy of Multiple Daily Administration of LFF571 for 10 Days in Patients With Moderate Clostridium Difficile Infections
Status: Enrolling
Updated:  6/5/2013
Novartis Investigative Site
mi
from
Bristol, CT
Safety and Efficacy of Multiple Daily Dosing of Oral LFF571 in Patients With Moderate Clostridium Difficile Infections
Multi-center, Randomized, Evaluator-blind, Active-controlled,Parallel-group Design to Determine Safety, Tolerability, and Efficacy of Multiple Daily Administration of LFF571 for 10 Days in Patients With Moderate Clostridium Difficile Infections
Status: Enrolling
Updated: 6/5/2013
Novartis Investigative Site
mi
from
Bristol, CT
Click here to add this to my saved trials
Safety and Efficacy of Multiple Daily Dosing of Oral LFF571 in Patients With Moderate Clostridium Difficile Infections
Multi-center, Randomized, Evaluator-blind, Active-controlled,Parallel-group Design to Determine Safety, Tolerability, and Efficacy of Multiple Daily Administration of LFF571 for 10 Days in Patients With Moderate Clostridium Difficile Infections
Status: Enrolling
Updated:  6/5/2013
Novartis Investigative Site
mi
from
Danbury, CT
Safety and Efficacy of Multiple Daily Dosing of Oral LFF571 in Patients With Moderate Clostridium Difficile Infections
Multi-center, Randomized, Evaluator-blind, Active-controlled,Parallel-group Design to Determine Safety, Tolerability, and Efficacy of Multiple Daily Administration of LFF571 for 10 Days in Patients With Moderate Clostridium Difficile Infections
Status: Enrolling
Updated: 6/5/2013
Novartis Investigative Site
mi
from
Danbury, CT
Click here to add this to my saved trials
Safety and Efficacy of Multiple Daily Dosing of Oral LFF571 in Patients With Moderate Clostridium Difficile Infections
Multi-center, Randomized, Evaluator-blind, Active-controlled,Parallel-group Design to Determine Safety, Tolerability, and Efficacy of Multiple Daily Administration of LFF571 for 10 Days in Patients With Moderate Clostridium Difficile Infections
Status: Enrolling
Updated:  6/5/2013
Novartis Investigative Site
mi
from
Danbury, CT
Safety and Efficacy of Multiple Daily Dosing of Oral LFF571 in Patients With Moderate Clostridium Difficile Infections
Multi-center, Randomized, Evaluator-blind, Active-controlled,Parallel-group Design to Determine Safety, Tolerability, and Efficacy of Multiple Daily Administration of LFF571 for 10 Days in Patients With Moderate Clostridium Difficile Infections
Status: Enrolling
Updated: 6/5/2013
Novartis Investigative Site
mi
from
Danbury, CT
Click here to add this to my saved trials